Venus Medtech (Hangzhou Venus Medical Devices Co.)

The primary focus of Venus Medtech is the development, manufacturing, and commercialization of transcatheter heart valve replacement and repair devices. These minimally invasive procedures offer alternatives to traditional open-heart surgery, reducing recovery times and improving outcomes for patients with various heart valve diseases.

Product Portfolio:

Venus Medtech has a diverse and growing portfolio of products and product candidates, including:

1. Transcatheter Aortic Valve Replacement (TAVR) Systems:

• VenusA-Valve: This is Venus Medtech's first-generation TAVR device and the first TAVR product approved for commercialization in China (April 2017). It features a unique stent design that allows for implantation without balloon pre-dilation and segmental release for stable and simplified operation. The radial force of the VenusA-Valve is enhanced to address the specific needs of Chinese patients, who often present with bicuspid aortic valves and heavy calcification. Clinical data has demonstrated its safety and efficacy with over five years of follow-up.
• VenusA-Plus: As the second-generation TAVR system from Venus Medtech (approved in November 2020), VenusA-Plus builds upon the strengths of the VenusA-Valve by incorporating a retrievable and repositionable delivery system. This advancement aims to simplify the procedure, increase the success rate, and improve postoperative outcomes. The retrievable feature helps to shorten the learning curve for physicians and accelerate the adoption of TAVR technology.
• VenusA-Pro: This represents the company's third-generation TAVR product. Specific details about VenusA-Pro might be more recently released and would likely include further advancements in valve design, delivery system, and clinical outcomes compared to its predecessors.
• Venus-Vitae: This next-generation balloon-expandable dry-tissue TAVR system utilizes the innovative Venus-Endura technology, which integrates multiple anti-calcification techniques for enhanced durability and biocompatibility. Its dry valve leaflet technology allows for room temperature storage and rapid preoperative preparation. The Venus-Vitae also features Lockwire Technology for stability during deployment and Coronary Alignment technology to aid in protecting coronary arteries. Its short stent frame and steerable delivery system optimize performance across the aortic arch.
• Venus-PowerX: This is the world's first fully released and retrievable self-expanding dry-tissue valve TAVR system. Its dry-tissue design offers improved durability and eliminates aldehyde residue. The wire-controlled retrieval mechanism enhances safety by allowing for repositioning even after full release. The delivery system is designed for optimal flexibility, and the valve frame is simplified to maintain coronary access.

2. Transcatheter Pulmonary Valve Replacement (TPVR) System:

• VenusP-Valve: This is the first self-expanding TPVR product approved in both China and Europe (CE marking under MDR in April 2022). It is designed with flared ends to ensure blood flow to the branchial artery and features bare stents at the outflow end for stable anchoring. The VenusP-Valve offers a wide range of sizes to accommodate various patient anatomies and eliminates the need for pre-stenting. Clinical data has shown excellent safety and efficacy, including high procedural success rates and low rates of reintervention and arrhythmia. It has received approval in over fifty countries, including Canada and Australia, and is undergoing pivotal clinical trials in the U.S.

3. Transcatheter Mitral and Tricuspid Valve Replacement (TMVR & TTVR):

• Cardiovalve: Through the acquisition of Cardiovalve Ltd., Venus Medtech has entered the TMVR and TTVR space. Cardiovalve is an innovative medical device designed for transcatheter valve replacement in both the mitral and tricuspid positions. It is currently undergoing clinical trials for both indications. This technology represents a significant expansion of Venus Medtech's portfolio to address the unmet needs in treating mitral and tricuspid regurgitation.

4. Hypertensive Renal Denervation (RDN) Therapy:

• Renaly System: Venus Medtech has established a joint venture (Renaly) to develop and commercialize next-generation innovative renal denervation (RDN) devices for the treatment of hypertension. RDN is a minimally invasive procedure that aims to lower blood pressure by reducing nerve activity in the renal arteries.

5. Accessory Products:

• G Sheath: An expandable catheter sheath product used as a procedural accessory in transcatheter interventions.
• TAV0 Balloon Catheter: A balloon catheter designed for aortic valvuloplasty, a procedure that may be performed prior to TAVR to prepare the native valve.
• V8/TAV8 Balloon Aortic Valvuloplasty Catheter Systems: Balloon catheters used for the dilation of the aortic valve.
• TriGUARD3 CEP Device: An anti-embolic distal brain protection device designed to reduce the risk of stroke during transcatheter aortic valve implantation procedures. This product came through the acquisition of Keystone Heart.

Research and Development:

Venus Medtech places a strong emphasis on research and development to drive innovation in the field of structural heart disease. The company has a robust pipeline of product candidates in various stages of development, covering all four heart valves and other cardiovascular interventions. They have established collaborations with international partners and invested significantly in developing novel technologies and materials, including dry-tissue valve technology. As of December 2023, Venus Medtech held over 800 patents and patent applications.

Manufacturing and Quality Standards:

As a medical device company, Venus Medtech adheres to stringent quality standards in the design, manufacturing, and distribution of its products. They likely operate state-of-the-art manufacturing facilities that comply with international regulations to ensure the safety and efficacy of their devices.

Market Presence and Strategy:

Venus Medtech has a strong market presence in China and is actively expanding its international footprint. Their strategy involves developing innovative products, conducting robust clinical trials, obtaining regulatory approvals in key markets, and building strong relationships with healthcare professionals. The company's commitment to providing comprehensive solutions for structural heart disease positions it as a significant player in the global cardiovascular medical device industry.

Acquisitions and Collaborations:

Venus Medtech has strategically pursued acquisitions and collaborations to enhance its technology portfolio and market access. These include the acquisition of Cardiovalve Ltd. and Keystone Heart, as well as joint ventures like Renaly and Venus Haoyue Medtech (focused on surgical heart valves and biomaterials). These initiatives demonstrate a commitment to expanding their offerings and strengthening their position in the broader cardiovascular market.

Conclusion:

Venus Medtech (Hangzhou Venus Medical Devices Co.) is a dynamic and innovative medical device company dedicated to advancing the treatment of structural heart diseases through minimally invasive transcatheter therapies. With a comprehensive product portfolio, a strong focus on R&D, and a growing global presence, Venus Medtech is well-positioned to continue its leadership in the field and provide significant benefits to patients worldwide.